In The News Posted January 6, 2020 Share Posted January 6, 2020 SAN DIEGO, Jan. 6, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced changes to their executive management team, effective immediately. Mirati continues to accelerate the development of the KRAS and sitravatinib... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.